Status:
COMPLETED
Utilizing Qualitative and Quantitative Methods to Understand a New Model of Type 1 and 2 Systemic Lupus Erythematosus (SLE)
Lead Sponsor:
Duke University
Collaborating Sponsors:
National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to pilot test SLE@Duke, a set of tools to implement the Type 1 \& 2 SLE Model in a clinical setting, as well as to gain an in-depth understanding of providers experiences ...
Eligibility Criteria
Inclusion
- All providers in Duke Rheumatology who practice outside of the Duke Lupus Clinic are eligible.
- Patients are eligible to participate if they have an established diagnosis of SLE and are followed in Duke Rheumatology.
- All patients with a SLE diagnosis will be included in the analysis. SLE diagnosis will be based on an ICD-10 code for SLE (M32.1\*, M32.8, M32.9) in the EMR.
Exclusion
- New patients will be excluded
Key Trial Info
Start Date :
January 3 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT05426902
Start Date
January 3 2022
End Date
June 30 2022
Last Update
September 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Medical Center
Durham, North Carolina, United States, 27710